医蛭唾液腺分泌物:成分、功能及应用前景

本文对医蛭唾液腺分泌物中主要活性物质的认识发现过程、结构与功能以及医学应用的实例和前景作了扼要的综述。     

大肠杆菌表达的重组葡激酶-水蛭素融合蛋白的分离纯化及其二聚体分析

采用阴离子交换和凝胶过滤色谱法纯化大肠杆菌高密度培养所表达的重组葡激酶－水蛭素融合蛋白（rSFH）,经SDS-PAGE和RP-HPLC分析纯度达到98％以上,每升发酵液得率约0.7g。同时利用疏水色谱、MALDI-TOF对纯化过程中出现的rSFH同源二聚体的分析和表面疏水面积的计算及利用高效排阻色谱（HPSEC）分析NaCl、温度对rSFH的可逆二聚化行为的影响,认为疏水作用在rSFH的可逆二聚化行为中发挥着重要作用。     

Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats

Although it has been reported that hirudin was excreted in urine mainly as its nonmetabolized form in humans, dogs, and rabbits, no report has been published about the molecular nature of urinary metabolites in rats. We found that nonmetabolized hirudin could not be detected in rat urine after its i.v. administration and that urinary metabolites of recombinant hirudin CX-397 consisted of at least the following six C-terminal-truncated peptides: CX-397^1–49, CX-397^1–50, CX-397^1–51, CX-397^1–52, CX-397^1–54, and CX-397^1–55, in the ratio of roughly 11, 51, 3, 11, 19, and 5%, respectively. In conclusion, the urinary metabolism of recombinant hirudin in rats is different from that in humans, dogs, and rabbits, suggesting that the handling of hirudin in rat kidney is unique among them.     

Assay of disulfide oxidase and isomerase based on the model of hirudin folding

Oxidative folding of fully reduced hirudin (R-Hir, six cysteines) undergoes two distinct stages. A first stage of nonspecific disulfide formation promoted by oxidase converts R-Hir to form 3-disulfide scrambled hirudins (X-Hir) as obligatory intermediates. A second stage of disulfide shuffling catalyzed by isomerase converts X-Hir to the native hirudin (N-Hir). The model of hirudin folding is utilized here to develop an assay system for measuring the activity of disulfide oxidase and isomerase, using high-performance liquid chromatography (HPLC) quantification of R-Hir, X-Hir, and N-Hir. The oxidase assay measures the ability of an oxidase to promote R-HirX-Hir conversion. The molar specific activity is expressed as mol ofR-Hir decrease per mol of oxidase per min. The isomerase assay measures the ability of an isomerase to catalyze X-HirN-Hir transformation. The molar specific activity is expressed as mol ofN-Hir increase per mol of isomerase per min. Alternatively, the recovery of N-Hir in the isomerase assay can be determined by its alpha-thrombin inhibitory activity. Using both HPLC and activity-based assay, we have measured the relative oxidase and isomerase activity of reduced and oxidized glutathione, Cys, Cys-Cys, and reduced and oxidized protein disulfide isomerase (PDI). The molar specific activity of reduced PDI was shown to be 0.1+/-0.01 U, which is consistent with documented data obtained by the scrambled RNase-A-based assay. These proposed assay methods provide alternatives to the limited option of methodologies currently available for measuring oxidase and isomerase activities. A major merit of the proposed assay system is the potential to accommodate the analysis of biological samples.     

毕赤酵母发酵生产中的水蛭素降解顺序

水蛭素 (rHV2 Lys4 7)是一个具有 65个氨基酸的抗凝活性肽。在毕赤酵母高密度发酵分泌表达过程中 ,发酵上清中可检出 4个水蛭素活性组份 ,分别为Hir65及其C 末端切除 1～ 3个氨基酸的Hir64、Hir63和Hir62。但目前 4种组份间的衍生关系还不清楚 ,以从发酵上清液中纯化分离所得的 4个组份作为底物 ,加入到菌体裂解液中 ,发现Hir64、Hir63和Hir62组份是由羧肽酶依次降解Hir65肽链C 末端 1个氨基酸后的产物。     

啤酒酵母生产的重组水蛭素的纯化及脱色

对啤酒酵母生产的重组水蛭素变异体1(rHV1)进行多步骤的纯化。首先将分泌到培养上清液中的水蛭素进行硫酸铵沉淀和SephadexG-50凝胶过滤,再用Q-SepharoseHP阴离子交换层析分离,最后用HPLCSP-5PW阳离子交换柱脱色及HPLCC8柱反相层析。真空干燥后得到的水蛭素蛋白经SPS-PAGE、N端氨基酸序列分析、抗凝血酶活力分析鉴定,证明已获得高纯度的重组水蛭素HV1制剂,为利用基因工程方法生产重组水蛭素的规模化生产及临床应用提供了依据     

表达重组葡激酶-水蛭素融合蛋白的大肠杆菌工程菌的高密度培养

采用溶氧反馈的分批培养流加补料的方法高密度培养重组大肠杆菌BL21(DE3)生产重组葡激酶-水蛭素融合蛋白。通过摇瓶培养对菌种和培养条件的初步筛选,采用溶氧反馈的流加补料策略,进行了5L发酵罐的合成培养基和复合培养基的发酵工艺的研究。通过对培养条件的不断优化,重组葡激酶-水蛭素融合蛋白在大肠杆菌BL21(DE3)里得到了高效表达,菌体密度最终达到115g/L(WCW)以上,可溶性重组融合蛋白占菌体总蛋白的30%以上,含量约为1.1~1.2g/L。5L发酵罐的发酵工艺参数在40L发酵罐中进行了放大培养,结果表明该工艺能有效的放大,可适用于工业生产。     

Unfolding of hirudin characterized by the composition of denatured scrambled isomers

The native core structure of hirudin, a thrombin specific inhibitor, contains 24 hydrogen bonds, two stretches of -sheet and three disulfide bonds. Hirudin unfolds in the presence of denaturant and thiol catalyst by shuffling its native disulfide bonds and converting to scrambled structures that consist of 11 identified isomers. The composition of scrambled isomers, which characterizes the structure of denatured hirudin, varies as a function of denaturing conditions. The unfolding pathway of hirudin has been constructed by quantitative analysis of scrambled isomers unfolded under increasing concentrations of various denaturants. The results demonstrate a progressive expansion of the polypeptide chain and the existence of a structurally defined stable intermediate along the pathway of unfolding.     

Structural differences in active site-labeled thrombin complexes with hirudin isoinhibitors

Hirudin, a 65 amino acid polypeptide from the medicinal leech, is the most potent thrombin inhibitor known to date. Recently, recombinant forms have been reported, which are as effective as the isolated forms. The studies presented here demonstrate sensitive spectroscopic methods for distinguishing binding of two recombinant hirudins, HV1 and HV2-Lys 47, with active site-labeled human -, - and -thrombins. Specifically, fluorosulfonylphenyl nitroxide spin labels, dansyl fluoride and p-nitrophenylanthranilate, were employed as active site-directed covalent reporter groups. In general, the nitroxide immobilization was greater for spin-labeled thrombin complexes with HV2-Lys 47 vs. HV1. The two fluorophore moieties, dansyl and anthraniloyl, were also sensitive to differences in HV1 and HV2-Lys 47 binding, including interactions with loop 145–150 of the thrombin structure where the - and -thrombin cleavages exist. Speculation over sequence differences between the two isoinhibitors centers on residues 24 and 47, both of which involve either a loss or gain of charge on the side chain.     

新型抗凝血药物的研究进展

当前临床上主要的抗凝血药物如肝素、华法林及重组水蛭素等存在出血,需要实验室监测,药物半衰期短等不足。以pegmusirudin、HD1-22、flovagatran、otamixaban、RB-006、EP217609等为代表的新型抗凝血药物克服了现有抗凝剂的诸多不足,为抗凝和溶栓治疗提供了更多选择。本文就相关研究及进展进行综述。